# INDEX

Volume 30 1975


A

Administrative Rule-Making. Aug., p. 478.

**Advertising in Canada**

Canadian Regulation of Food, Drugs, Cosmetics and Devices —An Overview. Nov., p. 644.

**Advisory Committees**

The FDA's Proposals for the Management of Advisory Committees. Aug., p. 503.

How to Let in the Sunshine Without Getting Burned: Protecting Your Rights Before Advisory Committees. Sept., p. 536.

America's First Food and Drug Laws. Nov., p. 665.

Angelotti, Robert.—Enforcement Policy Objectives in the Changing Food Environment. Dec., p. 712.

B

Barrows, Joseph.—Prescription Drug Labeling for Patients. Feb., p. 98.

Bartlett, Jeffrey W.—EEC Developments Affecting Products—Registration and Liability. Aug., p. 483.

Bass, Milton A.—Is the Substantive-Interpretive Issue Really Dead? Aug., p. 448.

**Bilingual Labeling**

Comments and Views from the Perspective of a Canadian Food Lawyer. Nov., p. 659.

Biological Perspectives on Approaches to Sensitivity of Analytical Methods for Tissue Residues. Feb., p. 124.

Boggan, E. Carrington—The FDA's Combination Drug Policy. May, p. 276.

Brandenburg, Robert C.—Information Requests Under the FOI Act. June, p. 321.

Bristol, Norman.—How Does One Get Rid of a Dead Horse? July, p. 421.

Burrell, Craig D.—Current Problems and Trends in Testing of Human Drugs—Especially in Regard to Institutional Review Committees. April, p. 213.

C

The Canadian Approach to Food and Drug Regulations. Nov., p. 632.

Canadian Regulation of Food, Drugs, Cosmetics and Devices—An Overview. Nov., p. 644.

**Carcinogens**

Biological Perspectives on Approaches to Sensitivity of Analytical Methods for Tissue Residues. Feb., p. 124.

Mantel-Bryan—Its Faults and Alternatives Available After Thirteen More Years of Experimentation. Feb., p. 116.

Chapman, D. G.—Current Topics in Canadian Food Regulatory Affairs. Nov., p. 654.

**Cholesterol**

Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

Christopher, Thomas H.—Free Speech and the Regulation of Labeling and Advertising. Sept., p. 512.

Cohen, Marsha.—Enforcement Under the Food, Drug and Cosmetic Act—The *Park* Case in Perspective. Dec., p. 676.

Cole, Richard and Shapiro, Marc.—Private Litigation Under the Federal Food, Drug and Cosmetic Act: Should the Right to Sue Be Implied? Oct., p. 576.

# INDEX

Volume 30 1975


A

Administrative Rule-Making. Aug., p. 478.

**Advertising in Canada**

Canadian Regulation of Food, Drugs, Cosmetics and Devices —An Overview. Nov., p. 644.

**Advisory Committees**

The FDA's Proposals for the Management of Advisory Committees. Aug., p. 503.

How to Let in the Sunshine Without Getting Burned: Protecting Your Rights Before Advisory Committees. Sept., p. 536.

America's First Food and Drug Laws. Nov., p. 665.

Angelotti, Robert.—Enforcement Policy Objectives in the Changing Food Environment. Dec., p. 712.

B

Barrows, Joseph.—Prescription Drug Labeling for Patients. Feb., p. 98.

Bartlett, Jeffrey W.—EEC Developments Affecting Products—Registration and Liability. Aug., p. 483.

Bass, Milton A.—Is the Substantive-Interpretive Issue Really Dead? Aug., p. 448.

**Bilingual Labeling**

Comments and Views from the Perspective of a Canadian Food Lawyer. Nov., p. 659.

Biological Perspectives on Approaches to Sensitivity of Analytical Methods for Tissue Residues. Feb., p. 124.

Boggan, E. Carrington—The FDA's Combination Drug Policy. May, p. 276.

Brandenburg, Robert C.—Information Requests Under the FOI Act. June, p. 321.

Bristol, Norman.—How Does One Get Rid of a Dead Horse? July, p. 421.

Burrell, Craig D.—Current Problems and Trends in Testing of Human Drugs—Especially in Regard to Institutional Review Committees. April, p. 213.

C

The Canadian Approach to Food and Drug Regulations. Nov., p. 632.

Canadian Regulation of Food, Drugs, Cosmetics and Devices—An Overview. Nov., p. 644.

**Carcinogens**

Biological Perspectives on Approaches to Sensitivity of Analytical Methods for Tissue Residues. Feb., p. 124.

Mantel-Bryan—Its Faults and Alternatives Available After Thirteen More Years of Experimentation. Feb., p. 116.

Chapman, D. G.—Current Topics in Canadian Food Regulatory Affairs. Nov., p. 654.

**Cholesterol**

Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

Christopher, Thomas H.—Free Speech and the Regulation of Labeling and Advertising. Sept., p. 512.

Cohen, Marsha.—Enforcement Under the Food, Drug and Cosmetic Act—The *Park* Case in Perspective. Dec., p. 676.

Cole, Richard and Shapiro, Marc.—Private Litigation Under the Federal Food, Drug and Cosmetic Act: Should the Right to Sue Be Implied? Oct., p. 576.

Collins, David E.—Recognition and Response—Critical Industry Needs. May, p. 299.

**Color Additives**
Cosmetic Ingredient Labeling—A Status Report. Feb., p. 129.
FDA Plans and Activities in the Food Area. April, p. 200.

**Combination Drugs**
The FDA's Combination Drug Policy. May, p. 276.
New Directions for Administrative Regulations. July, p. 384.

Comments and Views from the Perspective of a Canadian Food Lawyer. Nov., p. 659.

**Common Market**
EEC Developments Affecting Products—Registration and Liability. Aug., p. 483.

**Common or Usual Name Regulations**
Failure to Disclose Material Facts. May, p. 256.
Labeling of Foods. Dec., p. 706.
A Rose by Any Other Name. July, p. 415.

**Comparative Claims**
Questions and Answers. Mar., p. 183.
Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

The Consumer Product Safety Act—A Brief Overview. Sept., p. 555.

Condon, William J.—Product Liability—1974. May, p. 267.

**Confidentiality of Information**
Product Experience Reporting—An Industry View. April, p. 219.
Voluntary Cosmetic Product Experience Reporting—The FDA Viewpoint. April, p. 204.

**Contamination in Feed Ingredients**
What's New on the Horizon? Feb., p. 105.

Cosmetic Company Concerns and Opportunities—How We Will Cope. June, p. 350.

**Cosmetic Ingredient Labeling—A Status Report.** Feb., p. 129.

**Cosmetics Labeling**
Product Experience Reporting—An Industry View. April, p. 219.
What's on the Horizon? FDA's Plans, Priorities and Activities for Cosmetics. April, p. 233.
Working Out Cosmetic Ingredient Labeling or "The Little Engine That Could." April, p. 228.

Curran, Robert E.—Canadian Regulation of Food, Drugs, Cosmetics and Devices—An Overview. Nov., p. 644.

Current Problems and Trends in Testing of Human Drugs—Especially in Regard to Institutional Review Committees. April, p. 213.

Current Topics in Canadian Food Regulatory Affairs. Nov., p. 654.

**Cyclamates**
Current Topics in Canadian Food Regulatory Affairs. Nov., p. 654.

**D**

Dancing With the Gorilla. July, p. 410.

**Delaney Clause**
A Discussion of Assay Sensitivity Methodology and Carcinogenic Potential. Feb., p. 111.

Devices to Control Devices. July, p. 440.

**Diagnostics**
*In Vitro* Diagnostic Regulations—A Regulatory Ordeal. April, p. 247.
Recognition and Response—Critical Industry Needs. May. p. 299.
Regulatory Options and Ramifications of Recall. April, p. 239.

A Discussion of Assay Sensitivity Methodology and Carcinogenic Potential. Feb., p. 111.

**The *Dotterweich* Doctrine**
Personal Criminal Liability Under the Federal Food, Drug and Cosmetic Act—The *Dotterweich* Doctrine. Jan., p. 5.

Drug Company Concerns and Opportunities—How We Will Cope. June, p. 338.

Drug and Device Establishment Inspections. Oct., p. 613.

**Drug Reactions**

Prescription Drug Labeling for Patients. Feb., p. 98.

**Drugs in Animal Experimentation**

Regulatory and Scientific Matters Currently Confronting the Animal Health and Nutrition Industry. Feb., p. 85.

**E**

EEC Developments Affecting Products —Registration and Liability. Aug., p. 483.

Eiermann, Heinz J.—Cosmetic Ingredient Labeling—A Status Report. Feb., p. 129.

Enforcement Policy Objectives in the Changing Food Environment. Dec., p. 712.

Enforcement Under the Food, Drug and Cosmetic Act—The *Park* Case In Perspective, Dec., p. 676.

Epstein, Howard S.—New Directions for Administrative Regulations. July, p. 384.

**F**

FDA Plans and Activities in the Food Area. April, p. 200.

The FDA's Acceptance of Foreign Clinical Data. July, p. 433.

The FDA's Combination Drug Policy. May, p. 276.

The FDA's Freedom of Information Act Regulations. June, p. 312.

The FDA's Regulatory Proposals for the Management of Advisory Committees. Aug., p. 503.

Failure to Disclose Material Facts. May, p. 256.

**Failure-to-Warn Cases**

Product Liability—1974. May, p. 267.

**Fair Packaging and Labeling Act**

Working Out Cosmetic Ingredient Labeling or "The Little Engine That Could." April, p. 228.

**Federal Food, Drug and Cosmetic Act**

Free Speech and the Regulation of Labeling and Advertising. Sept., p. 512.

Private Litigation Under the Federal Food, Drug and Cosmetic Act: Should the Right to Sue Be Implied? Oct., p. 576.

Regulatory Options and Ramifications of Recall. April, p. 239.

Working Out Cosmetic Ingredient Labeling or "The Little Engine That Could." April, p. 228.

**Federal Pre-Emption**

What Price Uniformity? Sept., p. 567.

**First Amendment Protection**

Free Speech and the Regulation of Labeling and Advertising. Sept., p. 512.

**Food Additives**

Current Topics in Canadian Food Regulatory Affairs. Nov., p. 654.

Food Safety Review—New concepts for GRAS. May, p. 288.

Some Legal Aspects of Providing a Sufficient Food Supply for a Hungry Population. Sept., p. 527.

**Food Advertising**

Questions and Answers. Mar., p. 183.

Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

Trade Regulation Rule on Food Advertising—Remarks. Mar., p. 172.

Food Company Concerns and Opportunities—How We Will Cope. June, p. 345.

**Food and Drug Act of 1906**

Lawyers of the FDA—Yesterday and Today. Oct., p. 621.

Food Safety Review—New Concepts for GRAS. May, p. 288.

The Food and Drug Administration's Enforcement Policy. Dec., p. 687.

**Food Shortage**
What's New on the Horizon? Feb., p. 105.

**Fortification of Foods**
How Does One Get Rid of a Dead Horse? July, p. 421.

**Freedom of Information Act**
Cosmetic Company Concerns and Opportunities—How We Will Cope. June, p. 350.
Drug Company Concerns and Opportunities—How We Will Cope. June, p. 338.
Food Company Concerns and Opportunities—How We Will Cope. June, p. 345.
Information Requests Under the FOI Act. June, p. 321.

Panel Discussion. June, p. 354.
Problems and Opportunities Under the Public Information Regulations of the FDA. June, p. 326.
Regulatory and Scientific Matters Currently Confronting the Animal Health and Nutrition Industry. Feb., p. 85.

Free Speech and the Regulation of Labeling and Advertising. Sept., p. 512.

The Future of the Food and Drug Administration. Dec., p. 694.

G

Gass, George H.—A Discussion of Assay Sensitivity Methodology and Carcinogenic Potential. Feb., p. 111.

Giovacchini, Robert P.—The Significance of the Over-the-Counter Drug Review with Respect to the Safety Considerations of Cosmetic Ingredients. April, p. 223.

**GRAS Substances**
Food Safety Review—New Concepts for GRAS. May, p. 288.

H

Henteleff, Thomas O.—Drug and Device Establishment Inspections. Oct., p. 613.

Hill, Jefferson B.—Some Fundamentals of United States Antitrust Law. Sept., p. 45.

How Does One Get Rid of a Dead Horse? July, p. 421.

How to Let in the Sunshine Without Getting Burned: Protecting Your Rights Before Advisory Committees. Sept., p. 536.

Hutt, Peter Barton.—The Future of the Food and Drug Administration. Dec., p. 694.

I

*In Vitro* Diagnostic Regulations—A Regulatory Ordeal. April, p. 247.

**In Vivo Testing**
New Concepts in Abbreviated NDAs. July, p. 426.

Information Requests Under the FOI Act. June, p. 321.

**Inoculation**
America's First Food and Drug Laws. Nov., p. 665.

**Inspection Authority**
The Canadian Approach to Food and Drug Regulations. Nov., p. 632.
Drug and Device Establishment Inspections. Oct., p. 613.
Enforcement Policy Objectives in the Changing Food Environment. Dec., p. 712.

**Institutional Review Committees**
Current Problems and Trends in Testing of Human Drugs—Especially in Regard to Institutional Review Committees. April, p. 213.

**International Research**
The FDA's Acceptance of Foreign Clinical Data. July, p. 433.

**Interpretive Regulations**
Is the Substantive-Interpretive Issue Really Dead? Aug., p. 448.

Is the Substantive-Interpretive Issue Really Dead? Aug., p. 448.

J

Janssen, Wallace F.—America's First Food and Drug Laws. Nov., p. 665.

K

Kleinfeld, Vincent A.—Overview of Some Recent Developments in the Drug Field. Aug., p. 458.

L

Labeling of Foods. Dec., p. 706.

**Labeling Requirements for Foods**

Some Legal Aspects of Providing a Sufficient Food Supply for a Hungry Population. Sept., p. 527.

Lambert, Eugene I.

Dancing With the Gorilla. July, p. 410.

Working Out Cosmetic Ingredient Labeling or "The Little Engine That Could." April, p. 228.

**Lawmaking Function of Courts**

Private Litigation Under the Federal Food, Drug and Cosmetic Act: Should the Right to Sue Be Implied? Oct., p. 576.

Lawyers of the FDA—Yesterday and Today. Oct., p. 621.

**Licensing of drugs**

Safety, Efficacy and Quality Review in the United Kingdom. Aug., p. 495.

M

Manthei, Richard D.—*In Vitro* Diagnostic Regulations—A Regulatory Ordeal. April, p. 247.

Mantel-Bryan—Its Faults and Alternatives After Thirteen More Years of Experimentation. Feb., p. 116.

Marriott, J. V. R.—Safety, Efficacy and Quality Review in the United Kingdom. Aug., p. 495.

**Mathematical Models**

Biological Perspectives on Approaches to Sensitivity of Analytical Methods for Tissue Residue. Feb., p. 124.

Mantel-Bryan—Its Faults and Alternatives Available After Thirteen More Years of Experimentation. Feb., p. 116.

McGrew, Jane Lang.—How to Let in the Sunshine Without Getting Burned: Protecting Your Rights Before Advisory Committees. Sept., p. 536.

McKay, Francis E.—Lawyers of the FDA—Yesterday and Today. Oct., p. 621.

McKinley, Raymond E.—Regulatory and Scientific Matters Currently Confronting the Animal Health and Nutrition Industry. Feb., p. 85.

McNamara, Stephen H.—Some Legal Aspects of Providing a Sufficient Food Supply for a Hungry Population. Sept., p. 527.

**Meat Inspection**

USDA Plans, Priorities and Activities as They Affect the Food Industry and Consumers. Feb., p. 93.

**Medical Device Legislation**

Recognition and Response—Critical Industry Needs. May, p. 299.

**Medical Devices**

Devices to Control Devices. July, p. 440.

Drug and Device Establishment Inspections. Oct., p. 613.

Regulatory Options and Ramifications of Recall. April, p. 239.

**Medication**

Prescription Drug Labeling for Patients. Feb., p. 98.

Merrill, Richard A.

Administration Rule-Making. Aug., p. 478.

The *Park* Case. Dec., p. 683.

Middlekauff, Roger D.—Food Safety Review—New Concepts for GRAS. May, p. 288.

**Misbranding**

Failure to Disclose Material Facts. May, p. 256.

Morey, Richard S.—Publicity as a Regulatory Tool. Aug., p. 469.

Morrison, A. B.—The Canadian Approach to Food and Drug Regulations. Nov., p. 632.

Most, Jack L.—Cosmetic Company Concerns and Opportunities—How We Will Cope. June, p. 350.

Mussman, Harry C.—USDA Plans, Priorities and Activities as They Affect the Food Industry and Consumers. Feb., p. 93.

N

New Concepts in Abbreviated NDAs. July, p. 426.

New Directions for Administrative Regulations. July, p. 384.

**New Drug Applications**

Canadian Regulation of Food, Drugs, Cosmetics and Devices. Nov., p. 644.

Drug Company Concerns and Opportunities—How We Will Cope. June, p. 338.

The FDA's Combination Drug Policy. May, p. 276.

The FDA's Freedom of Information Act Regulations. June, p. 312.

New Concepts in Abbreviated NDAs. July, p. 426.

New Directions for Administrative Regulations. July, p. 384.

Overview of Some Recent Developments in the Drug Field. Aug., p. 458.

Panel Discussion. June, p. 354.

Problems and Opportunities Under the Public Information Regulations of the FDA. June, p. 326.

Recent Procedural Developments in FDA Regulations and Legislative Proposals. July, p. 396.

**Nitrites**

USDA Plans, Priorities and Activities as They Affect the Food Industry and Consumers. Feb., p. 93.

**Nutrient Levels**

Nutrition-Labeling Compliance. Feb., p. 89.

USDA Plans, Priorities and Activities as They Affect the Food Industry and Consumers. Feb., p. 93.

**Nutrition Labeling**

Questions and Answers. Mar., p. 183.

Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

Nutrition-Labeling Compliance. Feb., p. 89.

O

O'Keefe, Daniel F.—The FDA's Freedom of Information Act Regulations. June, p. 312.

O'Keefe, Daniel F. and Shapiro, Marc H.—Personal Criminal Liability Under the Federal Food, Drug and Cosmetic Act—The *Dotterweich* Doctrine. Jan., p. 5.

**Over-the-Counter Drug Review**

Recent Procedural Developments in FDA Regulations and Legislative Proposals. July, p. 396.

**Over-the-Counter Drugs**

The Significance of the Over-the-Counter Drug Review with Respect to the Safety Considerations of Cosmetic Ingredients. April, p. 223.

Overview of Some Recent Developments in the Drug Field. Aug., p. 458.

P

Panel Discussion. June, p. 354.

The *Park* Case. Dec., p. 683.

**The *Park* Decision**

Dancing With the Gorilla. July, p. 410.

Enforcement Under the Food, Drug and Cosmetic Act—The *Park* Case in Perspective. Dec., p. 676.

The Food and Drug Administration's Enforcement Policy. Dec., p. 687.

Personal Criminal Liability Under the Federal Food, Drug and Cosmetic Act—The *Dotterweich* Doctrine. Jan., p. 5.

**Patents**

Some Fundamentals of United States Antitrust Law. Sept., p. 545.

Pendergast, William R.—Problems and Opportunities Under the Public Information Regulations of the FDA. June, p. 326.

**Performance Standards**

Recognition and Response—Critical Industry Needs. May, p. 299.

Personal Criminal Liability Under the Federal Food, Drug and Cosmetic Act—The *Dotterweich* Doctrine. Jan., p. 5.

**Pharmaceutical Registration**

EEC Developments Affecting Products—Registration and Liability. Aug., p. 483.

Pietrangelo, Michael.—Product Experience Reporting—An Industry View. April, p. 219.

Pilot, Larry R.—Regulatory Options and Ramifications of Recall. April, p. 239.

**Polyvinyl chloride**

What's on the Horizon? FDA's Plans, Priorities and Activities for Cosmetics. April, p. 233.

Prescription Drug Labeling for Patients. Feb., p. 98.

Private Litigation Under the Federal Food, Drug and Cosmetic Act: Should the Right to Sue Be Implied? Oct., p. 576.

Problems and Opportunities Under the Public Information Regulations of the FDA. June, p. 326.

Product Experience Reporting—An Industry View. April, p. 219.

**Product Experience Reports**

What's on the Horizon? FDA's Plans, Priorities and Activities for Cosmetics. April, p. 233.

Voluntary Cosmetic Product Experience Reporting—The FDA Viewpoint. April, p. 204.

**Product Liability Law**

EEC Developments Affecting Products—Registration and Liability. Aug., p. 483.

Product Liability—1974. May, p. 267.

**Product Safety**

The Consumer Product Safety Act—A Brief Overview. Sept., p. 555.

**Protection of Human Subjects**

Current Problems and Trends in Testing of Human Drugs—Especially in Regard to Institutional Review Committees. April, p. 213.

Publicity as a Regulatory Tool. Aug., p. 469.

**Q**

Questions and Answers. Mar., p. 183.

Quinn, Taylor M.

FDA Plans and Activities in the Food Area. April, p. 200.

Labeling of Foods. Dec., p. 706.

**R**

Radzius, Joseph R.—Devices to Control Devices. July, p. 440.

Ragolia, William E.—The FDA's Acceptance of Foreign Clinical Data. July, p. 433.

**Recall of Products**

Devices to Control Devices. July, p. 440.

Publicity as a Regulatory Tool. Aug., p. 469.

Recent Procedural Developments in FDA Regulations and Legislative Proposals. July, p. 396.

Recognition and Response—Critical Industry Needs. May, p. 299.

**Recommended Daily Allowance**
Nutrition-Labeling Compliance. Feb., p. 89.
Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.
Trade Regulation Rule on Food Advertising—Remarks. Mar., p. 172.

Regulatory Options and Ramifications of Recall. April, p. 239.

Regulatory and Scientific Matters Currently Confronting the Animal Health and Nutrition Industry. Feb., p. 85.

Robb, James A.—Comments and Views from the Perspective of a Canadian Food Lawyer. Nov., p. 659.

Roberts, Howard R.—Nutrition-Labeling Compliance. Feb., p. 89.

Rosch, J. Thomas.—Trade Regulation Rule on Food Advertising—Remarks. Mar., p. 172.

A Rose by Any Other Name. July, p. 415.

**Rule-Making**
Administrative Rule-Making. Aug., p. 478.

Russell, Tomas M.—The Consumer Product Safety Act—A Brief Overview. Sept., p. 555.

**S**

Safety, Efficacy and Quality Review in the United Kingdom. Aug. p. 495.

Salsburg, David S.—Mantel-Bryan—Its Faults and Alternatives After Thirteen More Years of Experimentation. Feb., p. 116.

Sayer, Murray D.—A Rose by Any Other Name. July, p. 415.

Scarlett, Thomas.—The FDA's Regulatory Proposals for the Management of Advisory Committees. Aug., p. 503.

Schaffner, Robert M.—What's on the Horizon? FDA's Plans, Priorities and Activities for Cosmetics. April, p. 233.

Schmidt, Alexander M.—The Food and Drug Administration's Enforcement Policy. Dec., p. 687.

Seligman, David A.—Recent Procedural Developments in FDA Regulations and Legislative Proposals. July, p. 396.

Shapiro, Marc and Cole, Richard.—Private Litigation Under the Federal Food, Drug and Cosmetic Act: Should the Right to Sue Be Implied? Oct., p. 576.

Shapiro, Marc H. and O'Keefe, Daniel F.—Personal Criminal Liability Under the Federal Food, Drug, and Cosmetic Act—The *Dotterweich* Doctrine. Jan., p. 5.

**Sherman Act**
Some Fundamentals of United States Antitrust Law. Sept., p. 545.

The Significance of the Over-the-Counter Drug Review with Respect to the Safety Considerations of Cosmetic Ingredients. April, p. 223.

Some Fundamentals of United States Antitrust Law. Sept., p. 545.

Some Legal Aspects of Providing a Sufficient Food Supply for a Hungry Population. Sept., p. 527.

Spencer, Robert L.—New Concepts in Abbreviated NDAs. July, p. 426.

**Substitute Foods**
Current Topics in Canadian Food Regulatory Affairs. Nov., p. 654.
Some Legal Aspects of Providing a Sufficient Food Supply for a Hungry Population. Sept., p. 527.

Sunshine, Gary A.—Food Company Concerns and Opportunities—How We Will Cope.—June, p. 345.

**Superiority Claims**
Trade Regulation Rule on Food Advertising—Remarks. Mar., p. 172.

**T**

Thompson, Merrill S.—What Price Uniformity? Sept., p. 567.

**Toiletries Ingredients**
The Significance of the Over-the-Counter Drug Review with Respect to the Safety Considerations of Cosmetic Ingredients. April, p. 223.

Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

Trade Regulation Rule on Food Advertising—Remarks. Mar., p. 172.

**Trade Secrets**
The FDA's Freedom of Information Act Regulations. June, p. 312.
The FDA's Proposals for the Management of Advisory Committees. Aug., p. 503.
Panel Discussion. June, p. 354.
Problems and Opportunities Under the Public Information Regulations of the FDA. June, p. 326.

**U**

USDA Plans, Priorities and Activities as They Affect the Food Industry and Consumers. Feb., p. 93.

**V**

Van Houweling, C. D.—What's New on the Horizon? Feb., p. 105.

Voluntary Cosmetic Product Experience Reporting—The FDA Viewpoint. April, p. 204.

**W**

Weitzman, Stephen A.—Trade Regulation Rule on Food Advertising—An Analysis. Mar., p. 140.

Wenninger, John A.—Voluntary Cosmetic Product Experience Reporting—The FDA Viewpoint. April, p. 204.

What Price Uniformity? Sept., p. 567.

What's on the Horizon? FDA's Plans, Priorities and Activities for Cosmetics. April, p. 233.

What's New on the Horizon? Feb., p. 105.

Whyte, Warren E.—Drug Company Concerns and Opportunities—How We Will Cope. June, p. 338.

Williams, Jan Edward.—Failure to Disclose Material Facts. May, p. 256.

Working Out Cosmetic Ingredient Labeling or "The Little Engine That Could." April, p. 228.

**Z**

Zimbelman, Robert G.—Biological Perspectives on Approaches to Sensitivity of Analytical Methods for Tissue Residues. Feb., p. 124.